Literature DB >> 31378571

Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.

Christopher R M Asquith1, Neil Fleck2, Chad D Torrice3, Daniel J Crona4, Christoph Grundner5, William J Zuercher6.   

Abstract

We screened a series of 4-anilinoquinolines and 4-anilinoquinazolines and identified novel inhibitors of Mycobacterium tuberculosis (Mtb). The focused 4-anilinoquinoline/quinazoline scaffold arrays yielded compounds with high potency and the identification of 6,7-dimethoxy-N-(4-((4-methylbenzyl)oxy)phenyl)quinolin-4-amine (34) with an MIC90 value of 0.63-1.25 µM. We also defined a series of key structural features, including the benzyloxy aniline and the 6,7-dimethoxy quinoline ring, that are important for Mtb inhibition. Importantly the compounds showed very limited toxicity and scope for further improvement by iterative medicinal chemistry.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4-Anilinoquinazoline; 4-Anilinoquinoline; Anti-tubercular; Mycobacterium tuberculosis (Mtb)

Mesh:

Substances:

Year:  2019        PMID: 31378571      PMCID: PMC6736633          DOI: 10.1016/j.bmcl.2019.07.012

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

Review 1.  Current medical treatment for tuberculosis.

Authors:  Edward D Chan; Michael D Iseman
Journal:  BMJ       Date:  2002-11-30

2.  Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.

Authors:  Christopher R M Asquith; Kaleb M Naegeli; Michael P East; Tuomo Laitinen; Tammy M Havener; Carrow I Wells; Gary L Johnson; David H Drewry; William J Zuercher; David C Morris
Journal:  J Med Chem       Date:  2019-04-19       Impact factor: 7.446

3.  Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK).

Authors:  Christopher R M Asquith; Daniel K Treiber; William J Zuercher
Journal:  Bioorg Med Chem Lett       Date:  2019-05-16       Impact factor: 2.823

Review 4.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

Review 5.  Opportunities for Host-targeted Therapies for Malaria.

Authors:  Elizabeth K K Glennon; Selasi Dankwa; Joseph D Smith; Alexis Kaushansky
Journal:  Trends Parasitol       Date:  2018-08-16

6.  Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase.

Authors:  Christopher R M Asquith; Tuomo Laitinen; James M Bennett; Paulo H Godoi; Michael P East; Graham J Tizzard; Lee M Graves; Gary L Johnson; Ronna E Dornsife; Carrow I Wells; Jonathan M Elkins; Timothy M Willson; William J Zuercher
Journal:  ChemMedChem       Date:  2017-11-27       Impact factor: 3.466

Review 7.  Opportunities and Challenges for Host-Directed Therapies in Tuberculosis.

Authors:  Madhur Sachan; Ashish Srivastava; Rajeev Ranjan; Anuradha Gupta; Sanketkumar Pandya; Amit Misra
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 8.  The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.

Authors:  Katherine Floyd; Philippe Glaziou; Alimuddin Zumla; Mario Raviglione
Journal:  Lancet Respir Med       Date:  2018-04       Impact factor: 30.700

9.  Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence.

Authors:  Nuria Andreu; Taryn Fletcher; Nitya Krishnan; Siouxsie Wiles; Brian D Robertson
Journal:  J Antimicrob Chemother       Date:  2011-11-17       Impact factor: 5.790

10.  Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth.

Authors:  Sarah A Stanley; Amy K Barczak; Melanie R Silvis; Samantha S Luo; Kimberly Sogi; Martha Vokes; Mark-Anthony Bray; Anne E Carpenter; Christopher B Moore; Noman Siddiqi; Eric J Rubin; Deborah T Hung
Journal:  PLoS Pathog       Date:  2014-02-20       Impact factor: 6.823

View more
  5 in total

1.  Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype.

Authors:  Christopher R M Asquith; Louisa Temme; Michael P East; Tuomo Laitinen; Julie Pickett; Frank E Kwarcinski; Parvathi Sinha; Carrow I Wells; Gary L Johnson; Reena Zutshi; David H Drewry
Journal:  ChemMedChem       Date:  2022-05-09       Impact factor: 3.540

2.  New Insights into 4-Anilinoquinazolines as Inhibitors of Cardiac Troponin I-Interacting Kinase (TNNi3K).

Authors:  Christopher R M Asquith; Tuomo Laitinen; Carrow I Wells; Graham J Tizzard; William J Zuercher
Journal:  Molecules       Date:  2020-04-07       Impact factor: 4.411

3.  Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK).

Authors:  Christopher R M Asquith; James M Bennett; Lianyong Su; Tuomo Laitinen; Jonathan M Elkins; Julie E Pickett; Carrow I Wells; Zengbiao Li; Timothy M Willson; William J Zuercher
Journal:  Molecules       Date:  2019-11-06       Impact factor: 4.411

4.  Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors.

Authors:  Pei-Tzu Huang; Sirle Saul; Shirit Einav; Christopher R M Asquith
Journal:  Molecules       Date:  2021-12-03       Impact factor: 4.411

5.  Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform.

Authors:  Andrew A Bieberich; Tuomo Laitinen; Kaitlyn Maffuid; Raymond O Fatig; Chad D Torrice; David C Morris; Daniel J Crona; Christopher R M Asquith
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.